Drugs / YS110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03177668 | Aug 2017 → Feb 2020 | malignant pleural mesothelioma | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YS110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03177668 ↗ |
| Route | Intravenous | “Intravenous administration” NCT03177668 ↗ |